Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations
Cell Proliferation · 2024
DOI: 10.1111/cpr.13708 ↗At a glance
Journal article in Cell Proliferation, 2024. Written by Amanda Huee-Ping Wong and 11 co-authors. Institution: Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Tetraspanin 24, ErbB Receptors, Lung Neoplasms. Cited 5 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY 4.0). Funded by: National University Health Systems Bench-to-bedside grant, NUHS Cross Department Collaborative Grant.
Topics: Onkologische Pflege
Abstract (original language)
This study investigates CD151, a protein linked to cancer progression, in non‐small cell lung cancer (NSCLC) patients without epidermal growth factor receptor (EGFR) mutations. These patients often have limited treatment options. The study used retrospective analysis to examine 157 adenocarcinoma biopsy specimens and 199 patient cases from The Cancer Genome Atlas, correlating CD151 expression with patient survival. Cellular studies revealed that CD151 interacts with EGFR, influencing epidermal growth factor (EGF)‐induced cell proliferation and the effectiveness of the EGFR inhibitor, erlotinib. A strong association was found between CD151 expression and EGFR mutation status. High CD151 expression in the absence of EGFR mutations is correlated with poorer survival outcomes. Biological assays showed that CD151 colocalizes and associates with EGFR, playing a crucial role in regulating EGF‐induced cell proliferation via the AKT and ERK1/2 pathways. Importantly, CD151 expression was found to influence the anti‐proliferative effects of the EGFR tyrosine kinase inhibitor, erlotinib. High CD151 expression, in the absence of EGFR mutations, was associated with poorer survival outcomes. It could serve as a potential prognostic marker and influence cellular responses to EGFR‐targeted treatments. This study highlights CD151 as a potential novel target for therapeutic intervention in NSCLC, especially in populations lacking EGFR mutations.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Department of Pathology, National University Hospital, Singapore, Singapore.
- Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Department of Biostatistics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Department of Haematology-Oncology, National University Hospital, Singapore, Singapore.
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
ORCID profiles: Amanda Huee-Ping Wong, Omer An, John Kit Chung Tam, Thai Tran
Funding
- National University Health Systems Bench-to-bedside grant
- NUHS Cross Department Collaborative Grant
Cite
APA
Wong, A. H., Nga, M. E., Chin, C. Y., Tai, Y. K., Wong, H. C., Soo, R., An, O., Yang, H., Seet, J. E., Lim, Y. C., Tam, J. K. C., & Tran, T. (2024). Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations. Cell Proliferation. https://doi.org/10.1111/cpr.13708
Vancouver
Wong AH, Nga ME, Chin CY, Tai YK, Wong HC, Soo R, et al. Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations. Cell Proliferation. 2024. doi:10.1111/cpr.13708
BibTeX
@article{Wong2024,
author = {Wong, Amanda Huee-Ping and Nga, Min En and Chin, Chin Yein and Tai, Yee Kit and Wong, Hung Chew and Soo, Ross and An, Omer and Yang, Henry and Seet, Ju Ee and Lim, Yaw Chyn and Tam, John Kit Chung and Tran, Thai},
title = {Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations},
journal = {Cell Proliferation},
year = {2024},
doi = {10.1111/cpr.13708}
}
EUVIMED